Frequency of Renal Function Parameter Abnormalities in Patients with Psoriatic Arthritis and Rheumatoid Arthritis: Real-World Evidence from Clinical Practice
Abstract
:1. Introduction
2. Patients and Methods
2.1. Study Design and Patient Population
2.2. Clinical Assessments
2.3. Biochemical Assessments
2.4. Statistical Analysis
3. Results
3.1. Study Participants
3.2. Renal Function
3.3. Impact of Disease Remission or Relapse on Renal Function Parameters
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Kapoor, T.; Bathon, J. Renal manifestations of rheumatoid arthritis. Rheum. Dis. Clin. N. Am. 2018, 44, 571–584. [Google Scholar] [CrossRef] [PubMed]
- Ponticelli, C.; Doria, A.; Moroni, G. Renal disorders in rheumatologic diseases: The spectrum is changing (part 2. Arthridides). J. Nephrol. 2020, 34, 1081–1090. [Google Scholar] [CrossRef] [PubMed]
- Fayed, A.; Shaker, A.; Hamza, W.M.; Wadie, M. Spectrum of glomerulonephritis in Egyptian patients with rheumatoid arthritis: A University Hospital experience. Saudi J. Kidney Dis. Transplant. 2019, 30, 803–811. [Google Scholar] [CrossRef]
- Ayar, Y.; Ersoy, A.; Oksuz, M.F.; Ocakoglu, G.; Vuruskan, B.A.; Yildiz, A.; Isiktas, E.; Oruc, A.; Celikci, S.; Arslan, I.; et al. Clinical outcomes and survival in AA amyloidosis patients. Rev. Bras. Reumatol. Engl. Ed. 2017, 57, 535–544. [Google Scholar] [CrossRef] [PubMed]
- Engineer, D.P.; Kute, V.B.; Patel, H.V.; Shah, P.R. Clinical and laboratory profile of renal amyloidosis: A single-center experience. Saudi J. Kidney Dis. Transplant. 2018, 29, 1065–1072. [Google Scholar] [CrossRef]
- Laiho, K.; Tiitinen, S.; Kaarela, K.; Helin, H.; Isomäki, H. Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland. Clin. Rheumatol. 1999, 18, 122–123. [Google Scholar] [CrossRef]
- Pamuk, N.; Kalyoncu, U.; Aksu, K.; Omma, A.; Pehlivan, Y.; Çağatay, Y.; Küçükşahin, O.; Dönmez, S.; Çetin, G.Y.; Mercan, R.; et al. A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients. Rheumatol. Int. 2016, 36, 945–953. [Google Scholar] [CrossRef]
- Pamuk, O.N.; Dönmez, S.; Pamuk, G.E.; Puyan, F.O.; Keystone, E.C. Turkish experience in rheumatoid arthritis patients with clinical apparent amyloid deposition. Amyloid 2013, 20, 245–250. [Google Scholar] [CrossRef]
- Oweis, A.O.; Alawneh, K.M.; Alshelleh, S.A.; Alnaimat, F.; Alawneh, D.; Zahran, D.J. Renal dysfunction among rheumatoid arthritis patients: A retrospective cohort study. Ann. Med. Surg. 2020, 60, 280–284. [Google Scholar] [CrossRef]
- Sarnak, M.J.; Levey, A.S.; Schoolwerth, A.C.; Coresh, J.; Culleton, B.; Hamm, L.L.; McCullough, P.A.; Kasiske, B.L.; Kelepouris, E.; Klag, M.J.; et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 2003, 42, 1050–1065. [Google Scholar] [CrossRef]
- Chiu, H.-Y.; Huang, H.-L.; Li, C.-H.; Chen, H.-A.; Yeh, C.-L.; Chiu, S.-H.; Lin, W.-C.; Cheng, Y.-P.; Tsai, T.-F.; Ho, S.-Y. Increased risk of chronic kidney disease in rheumatoid arthritis associated with cardiovascular complications—A national population-based cohort study. PLoS ONE 2015, 10, e0136508. [Google Scholar] [CrossRef] [PubMed]
- Jankowski, J.; Floege, J.; Fliser, D.; Böhm, M.; Marx, N. Cardiovascular disease in chronic kidney disease: Pathophysiological insights and therapeutic options. Circulation 2021, 143, 1157–1172. [Google Scholar] [CrossRef] [PubMed]
- Bressolle, F.; Bologna, C.; Kinowski, J.-M.; Sany, J.; Combe, B. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann. Rheum. Dis. 1998, 57, 110–113. [Google Scholar] [CrossRef]
- Daoussis, D.; Panoulas, V.F.; Antonopoulos, I.; John, H.; Toms, T.; Wong, P.; Nightingale, P.; Douglas, K.M.J.; Kitas, G.D. Cardiovascular risk factors and not disease activity, severity or therapy associate with renal dysfunction in patients with rheumatoid arthritis: Table 1. Ann. Rheum. Dis. 2010, 69, 517–521. [Google Scholar] [CrossRef] [PubMed]
- Mori, S.; Yoshitama, T.; Hirakata, N.; Ueki, Y. Prevalence of and factors associated with renal dysfunction in rheumatoid arthritis patients: A cross-sectional study in community hospitals. Clin. Rheumatol. 2017, 36, 2673–2682. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Haroon, M.; Adeeb, F.; Devlin, J.; Ogradaigh, D.; Walker, F. A comparative study of renal dysfunction in patients with inflammatory arthropathies: Strong association with cardiovascular diseases and not with anti-rheumatic therapies, inflammatory markers or duration of arthritis. Int. J. Rheum. Dis. 2011, 14, 255–260. [Google Scholar] [CrossRef]
- Taylor, W.; Gladman, D.; Helliwell, P.; Marchesoni, A.; Mease, P.; Mielants, H.; CASPAR Study Group. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum. 2006, 54, 2665–2673. [Google Scholar] [CrossRef]
- Aletaha, D.; Neogi, T.; Silman, A.J.; Funovits, J.; Felson, D.T.; Bingham, C.O., III; Birnbaum, N.S.; Burmester, G.R.; Bykerk, V.P.; Cohen, M.D.; et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62, 2569–2581. [Google Scholar] [CrossRef]
- van der Heijde, D.M.; van’t Hof, M.; van Riel, P.L.; van de Putte, L.B. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J. Rheumatol. 1993, 20, 579–581. [Google Scholar]
- Cockcroft, D.W.; Gault, H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16, 31–41. [Google Scholar] [CrossRef]
- Atzeni, F.; Gerratana, E.; Masala, I.F.; Bongiovanni, S.; Sarzi-Puttini, P.; Rodríguez-Carrio, J. Psoriatic arthritis and metabolic syndrome: Is there a role for disease modifying anti-rheumatic drugs? Front. Med. 2021, 8, 735150. [Google Scholar] [CrossRef]
- Wibetoe, G.; Ikdahl, E.; Rollefstad, S.; Olsen, I.C.; Bergsmark, K.; Kvien, T.K.; Salberg, A.; Soldal, D.M.; Bakland, G.; Lexberg, Å.; et al. Cardiovascular disease risk profiles in inflammatory joint disease entities. Arthritis Res. Ther. 2017, 19, 153. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, T.; Liang, S.; Feng, X.; Li, M.; Zhou, H.; Zeng, C.; Zhang, J.; Cheng, Z. Spectrum and prognosis of renal histopathological lesions in 56 Chinese patients with rheumatoid arthritis with renal involvement. Clin. Exp. Med. 2020, 20, 191–197. [Google Scholar] [CrossRef] [PubMed]
- Mikhaylov, D.; Hashim, P.W.; Nektalova, T.; Goldenberg, G. Systemic psoriasis therapies and comorbid disease in patients with psoriasis: A review of potential risks and benefits. J. Clin. Aesthetic Dermatol. 2019, 12, 46–54. [Google Scholar]
- Stokes, M.B.; Foster, K.; Markowitz, G.S.; Ebrahimi, F.; Hines, W.; Kaufman, D.; Moore, B.; Wolde, D.; D’Agati, V.D. Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. Nephrol. Dial. Transplant. 2005, 20, 1400–1406. [Google Scholar] [CrossRef] [Green Version]
All Patients (n = 45) | PsA Patients (n = 23) | RA Patients (n = 22) | p-Value a | |
---|---|---|---|---|
Mean (SD) age, years | 55.6 (15.9) | 57.4 (10.2) | 54.3 (19.3) | 0.664 b |
Sex, n (%) | ||||
Male | 10 (22.2) | 6 (26.1) | 4 (18.2) | 0.722 |
Female | 35 (77.8) | 17 (73.9) | 18 (81.8) | |
Medical history, c n (%) | ||||
Hypertension | 11 (25.0) | 7 (31.8) | 4 (18.2) | 0.488 |
Diabetes mellitus | 5 (11.4) | 3 (13.6) | 2 (9.1) | 1.00 |
Autoimmune disease | 4 (9.1) | 3 (13.6) | 1 (2.3) | 0.607 |
Kidney failure | 1 (2.3) | 1 (2.3) | 0 | 1.00 |
Smoking, c n (%) | ||||
Never | 35 (79.5) | 21 (95.5) | 14 (63.6) | 0.029 d |
Former | 3 (6.8) | 0 | 3 (13.6) | |
Current | 6 (13.6) | 1 (4.5) | 5 (22.7) | |
Anti-CCP autoantibody positive, n (%) | 0 | 18 (80.7) | – | |
RF positive, n (%) | 0 | 16 (75.0) | – | |
Mean (SD) ESR, mm/h | 10.0 (8.7) | 35.0 (17.0) | – | |
Mean (SD) CRP, mg/dL | 9.0 (5.7) | 40.0 (20.7) | – | |
Concurrent hypertension diagnosis, e n (%) | 11 (25.6) | 9 (42.9) | 2 (9.1) | 0.016 |
Concomitant ACE inhibitors or ARBs, e n (%) | 8 (18.6) | 5 (23.8) | 3 (13.6) | 0.457 |
Variable, Mean (±SD) | PsA Patients (n = 23) | RA Patients (n = 22) | p-Value a |
---|---|---|---|
Weight, kg | 81.9 (11.2) | 67.6 (14.3) | 0.001 |
Height, m | 1.7 (0.1) | 1.6 (0.1) | 0.015 |
BMI, kg/m2 | 28.8 (3.5) | 25.0 (6.7) | 0.010 |
Variable, Mean ± SD | PsA Patients (n = 23) | RA Patients (n = 22) | p-Value a |
---|---|---|---|
Serum creatinine level, mg/dL | |||
At treatment initiation | 0.83 (0.20) | 0.79 (0.19) | 0.528 |
At 1 month | 0.78 (0.17) | 0.83 (0.18) | 0.302 |
At 3 months | 0.83 (0.17) | 0.83 (0.16) | 0.614 |
At 6 months | 0.89 (0.30) | 0.78 (0.15) | 0.466 |
At 12 months | 0.88 (0.29) | 0.82 (0.19) | 0.749 |
At the last assessment | 0.88 (0.20) | 0.83 (0.17) | 0.585 |
eGFR, mL/min/1.73 m2 | |||
At treatment initiation | 87.93 (19.62) b | 102.87 (45.88) | 0.510 |
At 1 month | 92.39 (18.57) c | 93.86 (32.13) | 0.699 |
At 3 months | 86.19 (16.88) d | 92.89 (29.37) | 0.939 |
At 6 months | 84.85 (23.18) e | 100.38 (35.78) | 0.345 |
At 12 months | 86.65 (26.88) f | 99.42 (47.99) | 0.807 |
At the last assessment | 82.29 (16.05) g | 96.02 (42.12) | 0.624 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Atzeni, F.; Muto, P.; Rodríguez-Carrio, J.; Masala, I.F. Frequency of Renal Function Parameter Abnormalities in Patients with Psoriatic Arthritis and Rheumatoid Arthritis: Real-World Evidence from Clinical Practice. J. Clin. Med. 2022, 11, 1029. https://doi.org/10.3390/jcm11041029
Atzeni F, Muto P, Rodríguez-Carrio J, Masala IF. Frequency of Renal Function Parameter Abnormalities in Patients with Psoriatic Arthritis and Rheumatoid Arthritis: Real-World Evidence from Clinical Practice. Journal of Clinical Medicine. 2022; 11(4):1029. https://doi.org/10.3390/jcm11041029
Chicago/Turabian StyleAtzeni, Fabiola, Pietro Muto, Javier Rodríguez-Carrio, and Ignazio Francesco Masala. 2022. "Frequency of Renal Function Parameter Abnormalities in Patients with Psoriatic Arthritis and Rheumatoid Arthritis: Real-World Evidence from Clinical Practice" Journal of Clinical Medicine 11, no. 4: 1029. https://doi.org/10.3390/jcm11041029
APA StyleAtzeni, F., Muto, P., Rodríguez-Carrio, J., & Masala, I. F. (2022). Frequency of Renal Function Parameter Abnormalities in Patients with Psoriatic Arthritis and Rheumatoid Arthritis: Real-World Evidence from Clinical Practice. Journal of Clinical Medicine, 11(4), 1029. https://doi.org/10.3390/jcm11041029